Clinical characteristics in antibody-positive pediatric patients with immune-mediated necrotizing myopathy Authors: Yiwen Xu, Zhanwei Zhang, Yixuan Chu, Fang He, Leilei Mao, Li Yang, Fei Yin, Jing Peng, Lifen Yang, Ciliu Zhang Published: 2026 ABSTRACT ObjectiveTo investigate the clinical characteristics and therapeutic strategies of childhood immune-mediated necrotizing myopathy (IMNM) and to provide evidence for clinical diagnosis and management.MethodsThis single-center retrospective study analyzed the clinical data of 10 children diagnosed with antibody-positive IMNM at the Children’s Medical Center, Xiangya Hospital, Central South University, from January 2016 to May 2025. The onset features, clinical manifestations, laboratory findings, muscle magnetic resonance imaging (MRI) characteristics, treatment modalities, and prognosis were summarized.ResultsAmong the 10 patients, 4 were male and 6 were female, with a median age at onset of 5.5 years (range: 3–16 years). The main clinical manifestations included symmetric proximal muscle weakness (100%) and cutaneous manifestations (50%, including Gottron’s sign and periorbital rash). Creatine kinase (CK) levels were markedly elevated, with a median of 3988.5 U/L (range: 2080–13524 U/L). Muscle MRI revealed edema or fatty infiltration in the thigh muscles. Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies were detected in 4 patients (40%), and anti-signal recognition particle (SRP) antibodies in 6 patients (60%). Electromyography (EMG) showed myopathic changes in all tested cases (8/10 patients). Muscle histopathology was available for one patient, demonstrating myofiber necrosis, regeneration, and inflammatory cell infiltration. All patients received glucocorticoid therapy, combined with oral methotrexate. Additionally, 5 patients were treated with rituximab, and 9 patients received intravenous immunoglobulin (IVIG). During follow-up, 2 patients achieved complete remission, 1 patient showed partial remission, 3 patients exhibited no significant remission, and 4 patients experienced relapse.ConclusionChildhood IMNM is characterized by proximal muscle weakness, typical rash, and significantly elevated CK levels, frequently accompanied by anti-SRP or anti-HMGCR antibodies. Early immunosuppressive therapy, including glucocorticoids combined with immunosuppressants or IVIG, may be associated with clinical improvement in this small retrospective series.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13052-026-02278-7. Introduction Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders characterized by chronic muscle inflammation and weakness. These conditions include dermatomyositis (DM), polymyositis (PM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). The principal clinical manifestations of IIMs encompass symmetric proximal muscle weakness, elevated serum muscle enzyme levels, presence of autoantibodies, and inflammatory cell infiltration in muscle histopathology. The disease exhibits two peak incidence periods: 45–60 years and 5–15 years, with a higher prevalence in adults [1]. At the 119th international workshop of the European Neuromuscular Centre (ENMC), the sub-group of “IMNM” emerged as a separate entity among IIMs for the first time based on pathological criteria [2]. The characteristics of IMNM have some similarity with IIMs, but it progresses more rapidly. Among pediatric patients, the morbidity of IMNM is less than juvenile dermatomyositis (JDM) in juvenile IIMs. One previous research stated that pediatric IMNM accounts for just 2.9% of 440 juvenile IIMs, which is significantly lower than that in adult IMNM [3]. With a deeper understanding of IMNM, it is further subdivided into three subtypes based on the presence of myositis-specific autoantibodies (MSAs) according to the 2016 ENMC classification criteria: anti-signal recognition particle (SRP) antibody-positive, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody-positive, and seronegative cases [4]. However, comprehensive data on the clinical spectrum and outcomes of pediatric IMNM remain limited. While substantial clinical data exist regarding adult IMNM, including its clinical features, treatment modalities, and prognostic factors, evidence on pediatric IMNM still has limitations. This study presents a retrospective analysis of clinical data from 10 pediatric patients diagnosed with antibody-positive IMNM, aiming to describe the clinical manifestations, serological profiles, therapeutic strategies, and outcomes. The findings are intended to enhance clinical awareness of pediatric antibody-positive IMNM, facilitate early diagnosis, guide individualized treatment, and provide a foundation for future prospective research on this rare condition. Methods Diagnostic criteria and patient enrollment Clinical data were retrospectively collected and analyzed from pediatric patients diagnosed with IMNM at the Children’s Medical Center, Xiangya Hospital, Central South University, between January 2016 and May 2025. The inclusion criteria were as follows: (1) patients were under 18 years old at disease onset; (2) the diagnosis conformed to the most recent European Neuromuscular Center (ENMC) criteria which consist of elevated creatine kinase (CK) levels, proximal muscle weakness, seropositivity for anti-HMGCR or anti-SRP antibodies; (3) seronegative patients presented with specified muscle biopsy characteristics [4]; (4) informed consent was obtained from all patients’ legal guardians. Patients were excluded if they met any of the following criteria: (1) the clinical data were incomplete, (2) lack of muscle biopsy characteristics in patients without these two specific antibodies. We collected a total of 60 pediatric patients with IIMs, of whom 17 patients were seronegative. Among these antibody-negative patients, 6 underwent muscle biopsy, but they did not meet the specified muscle biopsy characteristics of IMNM. Then, there were 10 antibody-positive patients with IMNM enrolled eventually. The data encompassed clinical presentations, laboratory findings, treatment regimens, and outcomes. In addition, targeted genetic sequencing for common childhood-onset muscular dystrophies, including mutations in the DMD gene, LGMD-related genes and so on, was conducted to exclude inherited myopathies. These gene panels consisted of Duchenne Muscular Dystrophy-Multiplex Ligation-dependent Probe Amplification (DMD-MLPA), Neuromuscular Gene Panel, Single Individual Whole Exome Sequencing and Trio-Whole Exome Sequencing, which were constructed based on published literature, the Online Mendelian Inheritance in Man (OMIM) database and American College of Medical Genetics and Genomics (ACMG) guidelines [5]. The study was approved by the Medical Ethics Review Committee of Xiangya Hospital, Central South University (202307148-2, Date of approval: March 6th, 2025), conducted in accordance with the principles of the Declaration of Helsinki. Antibodies detection Serum myositis autoantibodies were detected using Euroimmun immunoblot assays, following the manufacturer’s instructions as previously described [6]. Assay procedures followed the standard protocol of Euroimmun Line Immunoassay in a medical laboratory, which had achieved the Quality Assessment Report QV 1530-240312 (Myopathies I/2024, “Antibodies in autoimmune myopathies”) from DAkkS (Deutsche Akkreditierungsstelle). As a signatory to the ilac-MRA (International Laboratory Accreditation Cooperation Mutual Recognition Arrangement), DAkkS accreditation ensures the global equivalence and acceptability of the test results, confirming the reliability and reproducibility of the assay data in this study. The panel included anti-Mi-2, anti-TIF1γ, anti-NXP2, anti-Ku, anti-PM-Scl75, anti-PM-Scl100, anti-SRP, anti-PL-7, anti-PL-12, anti-OJ, anti-cN-1 A, anti-MDA5, anti-SAE1, anti-Jo-1, anti-EJ, anti-Ro-52, and anti-HMGCR antibodies. Immunoblot results were interpreted as weakly positive or doubtful (+), positive (+ or ++), or strongly positive (+++) based on the intensity of the reaction bands. For the EURO-Line-Scan assay, result interpretation was performed by correlating visual staining intensity with the quantitative staining intensity following this assay protocol criteria: (1) when the visual staining was colorless, the corresponding EURO-Line-Scan staining intensity ranged 0–5, and the result was categorized as negative (-); (2) for very weak visual staining, the intensity was 6–10, corresponding to a result of weakly positive or doubtful (+); (3) in cases of moderate to strong visual staining, the intensity was 11–25 or 26–50, with results recorded as positive (+ or ++); (4) if the visual staining intensity was identical to that of the control band, the intensity exceeded 50, and the result was designated as strongly positive (+++). Muscle magnetic resonance imaging parameters Muscle magnetic resonance imaging (MRI) was performed using either a 1.5 Tesla or 3.0 Tesla scanner (Siemens, Erlangen, Germany) at Xiangya Hospital. The MRI protocol included coronal and axial T1-weighted, T2-weighted, and short-tau inversion recovery (STIR) sequences. Imaging parameters were as follows: T1-weighted—repetition time (TR) 480 ms, echo time (TE) 13 ms, slice thickness 4 mm; T2-weighted—TR 3280 ms, TE 65 ms, slice thickness 4 mm. Assessment of muscular fatty infiltration and edema The degree of fatty infiltration was assessed on T1-weighted images based on a previously established classification system [7], modified and categorized into six grades: 0, normal; 1, scattered signals; 2, mild abnormalities (< 30% fatty infiltration); 3, moderate abnormalities (30–60% fatty infiltration); 4, severe abnormalities (> 60% fatty infiltration); 5, complete replacement of muscle tissue by fatty infiltration. Muscle edema was graded based on STIR sequences using a six-point scale as follows [8]: 0, normal; 1, scattered high signals without fusion; 2, slightly high scattered or small sheet-like signals involving less than 50% of the muscle; 3, higher scattered or small sheet-like signals involving less than 50%; 4, slightly high scattered or small sheet-like signals involving more than 50%; 5, higher scattered or small sheet-like signals involving more than 50%. The muscular MRI was assessed and reviewed by two independent experts who majored in neuromuscular imaging and pediatric neuromuscular disorders and were blinded to clinical data. If the two experts were inconsistent, a third professor was invited to evaluate. Muscle biopsy Muscle biopsy specimens were obtained, frozen, sectioned, and fixed. Subsequently, they were stained with hematoxylin and eosin (HE) and immunostained with antibodies against C5b-9, CD4, CD8, CD20, CD68, major histocompatibility complex class I (MHC-I), and dystrophin (rod domain). Acid-fast staining techniques were employed to detect structural abnormalities in muscle biopsies. Nicotinamide adenine dinucleotide hydrogenase (NADH) staining was performed to evaluate mitochondrial enzyme activity and the internal architecture of muscle fibers [9]. Follow up and outcome From January 2016 to May 2025, a total of 10 patients were followed up. During the follow-up period, manual muscle testing (MMT) (Table 1) [10] and serum CK levels were used to evaluated disease activity as the outcome measures. Besides, quality of life assessment using the modified Rankin Scale (mRS) (Table 2) [11, 12] was performed, with initial, best, and final mRS scores documented. MMT focused on key proximal muscle groups (deltoid and quadriceps) and was performed independently by two experienced neuromuscular specialists following standardized Medical Research Council (MRC) guidelines. Patients with cervical muscle involvement were classified as having axial muscle weakness, while the remaining patients were categorized as having limb muscle involvements. Treatment outcomes were classified as complete remission, partial remission, no significant improvement, and relapse. Complete remission was defined as nearly normal CK levels, normal muscle power and an mRS score of 0. Partial remission was defined as slightly high CK levels and/or muscle power and an mRS score of 1. No significant improvement referred to significantly high CK levels (≥1000U/L) and/or weak muscle power (MMT≤3) and an mRS score equal to or greater than 3. Relapse was defined as CK level elevation more than twice as much as the initial level, and/or that MMT grade and/or mRS scores became less than before when the dose of medicines started to reduce the dose of medicines. Table 1The Manual Muscle Testing (MMT)GradeDescription0No contraction1Flicker or trace of contraction2Active movement with gravity eliminated3Active movement against gravity4Active movement against gravity and resistance5Normal power Table 1The Manual Muscle Testing (MMT)GradeDescription0No contraction1Flicker or trace of contraction2Active movement with gravity eliminated3Active movement against gravity4Active movement against gravity and resistance5Normal power The Manual Muscle Testing (MMT) Table 2The modified Rankin Scale (mRS)Rankin GradeDescription0No symptoms1No significant disability: despite symptoms able to carry out all usual duties and activities2Slight disability: unable to perform all previous activities but able to look after own affairs without assistance3Moderate disability: requiring some help, but able to walk without assistance4Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance5Severe disability: bedridden, incontinent, and requiring constant nursing care and attention6Death Table 2The modified Rankin Scale (mRS)Rankin GradeDescription0No symptoms1No significant disability: despite symptoms able to carry out all usual duties and activities2Slight disability: unable to perform all previous activities but able to look after own affairs without assistance3Moderate disability: requiring some help, but able to walk without assistance4Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance5Severe disability: bedridden, incontinent, and requiring constant nursing care and attention6Death The modified Rankin Scale (mRS) Statistical analysis This was a retrospective observational study. As such, the data analysis plan was not prespecified in a formal protocol prior to data collection. All reported analyses are therefore considered post-hoc and exploratory. And all study variables were complete for all participants included in the final analysis (n = 10). No missing data were present, and therefore, no imputation or exclusion procedures were necessary. We have adhered to the STROBE guidelines to ensure transparency in reporting our findings (Supplementary materials Table S2). Statistical analysis was conducted using SPSS version 27.0 software. Normally distributed continuous variables were expressed as mean ± standard deviation, whereas non-normally distributed data were presented as median (interquartile range). Inter-rater reliability was assessed using overall percentage agreement and linear weighted kappa coefficients with 95% confidence intervals [13]. Weighted kappa values of 0.61–0.80 and ≥ 0.81 were defined as good and excellent reliability, respectively, according to established criteria for muscle MRI scoring [14]. Results Clinical features According to established criteria, 10 antibody-positive patients with IMNM were ultimately enrolled. Table 3 summarizes the clinical characteristics of patients. The cohort consisted of 6 females and 4 males. The median age at disease onset was 5.5 years (range: 3–16 years). Myositis antibody testing demonstrated positivity for anti-HMGCR antibody in 4 patients and anti-SRP antibody in 6 patients. Overlapping myositis antibodies were detected in 2 patients with anti-HMGCR and 2 with anti-SRP antibodies. None of the anti-HMGCR-positive patients had prior statin exposure. All patients presented with muscle weakness affecting both upper and lower limbs, while isolated lower limb involvement was observed in 1 patient. Axial muscle weakness was documented in 3 patients, manifesting as impaired neck flexion or rotation, weak shoulder shrugging, or abduction. Lower limb myalgia was reported in case 2 and case 6. No patient exhibited respiratory or cardiac symptoms. Gottron’s sign and periorbital rash were observed in 1 patient with anti-HMGCR and 4 patients with anti-SRP antibody, respectively. In case 1 and case 5, cutaneous manifestations occurred 10 and 18 months, respectively, before the onset of muscle weakness, suggesting these signs may serve as early indicators of IMNM. Case 1 was also diagnosed with subclinical hypothyroidism. No patient had coexisting rheumatic disease. Laboratory data The median initial CK level was 3988.5 U/L (range: 2080–13524 U/L; normal reference range: 50–310 U/L). Elevated CK levels were detected in case 2 and case 4, 9 and 12 months before the onset of muscle weakness, respectively. The median peak and final CK levels were 10,228 (range: 2080–16674) U/L and 377.5 (range: 58–2514) U/L. At the last follow-up, 5 patients had elevated CK levels, and among them, 4 remained asymptomatic or experienced only mild symptoms. In four HMGCR antibody-positive patients, the median initial, highest, and final CK levels were 6280.5 (range: 3270–13524) U/L, 14324.5 (range: 10482–16674) U/L, and 1537.5 (range: 589–1778) U/L, respectively. In contrast, among five SRP antibody-positive patients, the corresponding values were 3171.5 (range: 2080–11836) U/L, 7205.5 (range: 2080–11836) U/L, and 102.5 (range: 58–668) U/L, with two patients exhibiting peak CK levels at disease onset (Table 5). Table 3Clinical features of patients with IMNMGenderOnset of age, yearTime to diagnosis, monthsAntibodyMuscle weaknessLung disease#Cardiac involvement*Skin rashCase 1Female392HMGCRupper and lower limbs, especially proximalNoNoGottron sign in handsCase 2Female664HMGCRupper and lower limbs, especially proximalcervical muscleNoNoNoCase 3Male324HMGCR, Mi-2lower limbs, especially proximalcervical muscleNoNoNoCase 4Female1215HMGCR, NXP2, PL-7upper and lower limbs, especially proximalNoNoNoCase 5Male1138SRPupper and lower limbs, especially proximalNoNoPeriorbital rash, Gottron sign in handsCase 6Female530SRP, PM-Scl 75upper and lower limbs, especially proximalNoNoNoCase 7Female164SRPupper and lower limbs, especially proximalcervical muscleNoNoPeriorbital purple rash, Gottron sign in handsCase 8Female416SRP, Ro-52, PM-Scl 75upper and lower limbs, especially proximalNoNoNoCase 9Male54SRPupper and lower limbs, especially proximalNoNoPeriorbital rash, Gottron sign in hands and kneesCase 10Male113SRPupper and lower limbs, especially proximalNoNoPeriorbital rash# Lung disease was operationalized by chest high-resolution computed tomography* Cardiac involvement was operationalized by electrocardiography and echocardiography Table 3Clinical features of patients with IMNMGenderOnset of age, yearTime to diagnosis, monthsAntibodyMuscle weaknessLung disease#Cardiac involvement*Skin rashCase 1Female392HMGCRupper and lower limbs, especially proximalNoNoGottron sign in handsCase 2Female664HMGCRupper and lower limbs, especially proximalcervical muscleNoNoNoCase 3Male324HMGCR, Mi-2lower limbs, especially proximalcervical muscleNoNoNoCase 4Female1215HMGCR, NXP2, PL-7upper and lower limbs, especially proximalNoNoNoCase 5Male1138SRPupper and lower limbs, especially proximalNoNoPeriorbital rash, Gottron sign in handsCase 6Female530SRP, PM-Scl 75upper and lower limbs, especially proximalNoNoNoCase 7Female164SRPupper and lower limbs, especially proximalcervical muscleNoNoPeriorbital purple rash, Gottron sign in handsCase 8Female416SRP, Ro-52, PM-Scl 75upper and lower limbs, especially proximalNoNoNoCase 9Male54SRPupper and lower limbs, especially proximalNoNoPeriorbital rash, Gottron sign in hands and kneesCase 10Male113SRPupper and lower limbs, especially proximalNoNoPeriorbital rash# Lung disease was operationalized by chest high-resolution computed tomography* Cardiac involvement was operationalized by electrocardiography and echocardiography Clinical features of patients with IMNM upper and lower limbs, especially proximal cervical muscle lower limbs, especially proximal cervical muscle upper and lower limbs, especially proximal cervical muscle # Lung disease was operationalized by chest high-resolution computed tomography * Cardiac involvement was operationalized by electrocardiography and echocardiography Thigh MRI All patients underwent muscle magnetic resonance imaging (MRI). Edema and fatty infiltration were assessed using a 5‑point ordinal scale (0–5) across a total of 120 muscle segments from 10 patients. For the edema score, the overall percentage agreement between the two raters was 92.50%, with a linear weighted kappa coefficient of 0.910 (95% confidence interval [CI]: 0.86–0.95). For the fatty infiltration score, the overall percentage agreement was 94.17%, with a linear weighted kappa coefficient of 0.932 (95% CI: 0.89–0.96). According to established criteria for muscle MRI scoring, both kappa values indicate excellent inter‑rater reliability. As shown in Fig. 1, thigh MRI revealed muscle edema in 8 of 10 patients, while fatty infiltration was observed in 5 patients (Figs. 1 and 3). The frequency and mean scores of muscle edema were highest in the adductor magnus, whereas the gluteus maximus showed the highest mean scores and frequency for fatty infiltration (Figs. 2 and 3). Per-muscle scores are provided in Supplementary Table S1. Fig. 1Muscle edema and fatty infiltration scores for each case in first thigh MRI. Abbreviations: RF, rectus femoris; Sa, sartorius; Gr, gracilis; VL, vastus lateralis; VM, vastus medialis; VI, vastus intermedius; AL, adductor longus; AM, adductor magnus; Sm, semimembranosus; St, semitendinosus; BF, biceps femoris; GM, gluteus maximus Muscle edema and fatty infiltration scores for each case in first thigh MRI. Abbreviations: RF, rectus femoris; Sa, sartorius; Gr, gracilis; VL, vastus lateralis; VM, vastus medialis; VI, vastus intermedius; AL, adductor longus; AM, adductor magnus; Sm, semimembranosus; St, semitendinosus; BF, biceps femoris; GM, gluteus maximus Fig. 2(a) The Line Graph of edema and fatty infiltration mean scores. (b) The Line Graph of edema and fatty frequency (a) The Line Graph of edema and fatty infiltration mean scores. (b) The Line Graph of edema and fatty frequency Fig. 3Representative thigh MRI findings of muscle edema and fatty infiltration. (a, b) Muscle edema is shown on STIR imaging. (c, d) Muscle fatty infiltration is shown on T1-weighted imaging Representative thigh MRI findings of muscle edema and fatty infiltration. (a, b) Muscle edema is shown on STIR imaging. (c, d) Muscle fatty infiltration is shown on T1-weighted imaging Electromyogram and myopathology Among the ten patients, eight underwent needle electromyography, all demonstrating myogenic changes. Muscle biopsy results were available for only one HMGCR antibody-positive patient. The biopsy was taken from the left biceps brachii muscle. Hematoxylin and eosin staining revealed marked variability in myofiber size, scattered necrotic and regenerating myofibers, and moderate connective tissue proliferation. NADH dehydrogenase staining showed disruption of the intermyofibrillar network in most myofibers. Acid phosphatase staining demonstrated scattered focal increases in endomysial enzyme activity. No abnormalities were detected on Gomori staining, adenosine monophosphate (AMP) activity, succinate dehydrogenase staining, cytochrome C oxidase and succinate double staining, adenosine triphosphate (ATP) cyclase staining, or PAS and ORO staining. Immunohistochemical analyses for muscular dystrophy and inflammatory myopathy were also performed. In the muscular dystrophy panel, anti-dystrophin-R, -C, -N staining of dystrophin protein in muscle fiber membranes, anti-myosin-α, -β, -γ, -δ staining of myosin protein in the endomysium, and anti-dysferlin staining all showed normal expression. However, the inflammatory myopathy panel revealed characteristic findings: major histocompatibility complex class Ⅰ (MHC-Ⅰ) expression was positive in necrotic myofibers; numerous CD4-positive lymphocytes, a few CD8-positive lymphocytes, and a few CD68-positive macrophages were present in the endomysium; partial expression of the C5b-9 membrane attack complex (MAC) in the myofiber cytoplasm. No CD20-positive lymphocytes were observed (Fig. 4). Fig. 4Representative muscle biopsy findings in Case 2 with HMGCR antibody positivity. Hematoxylin and eosin staining (a). NADH dehydrogenase staining (b). Acid phosphatase staining (c). MHC-I expression (d). CD4-positive and CD8-positive lymphocytes, and CD68-positive macrophages in the endomysium (e, f, g). MAC immunohistochemical staining (h) Representative muscle biopsy findings in Case 2 with HMGCR antibody positivity. Hematoxylin and eosin staining (a). NADH dehydrogenase staining (b). Acid phosphatase staining (c). MHC-I expression (d). CD4-positive and CD8-positive lymphocytes, and CD68-positive macrophages in the endomysium (e, f, g). MAC immunohistochemical staining (h) Treatment and outcome All pediatric patients received initial corticosteroid therapy during follow-up until May 2025, including six patients treated with intravenous methylprednisolone pulse therapy and four patients receiving oral prednisolone. The median duration of steroid maintenance therapy was 36.5 months (range: 9–74 months). Additionally, these 10 patients received various immunotherapeutic interventions, including intravenous immunoglobulin (IVIG) (n = 9), methotrexate (n = 10), rituximab (RTX) (n = 5), mycophenolate mofetil (n = 2), tacrolimus (n = 2), azathioprine (n = 1), telitacicept (n = 1), and ofatumumab (n = 1). 6 patients received a combination of glucocorticoids and IVIG as initial induction therapy, among whom two also received RTX as part of upfront treatment (Table 4). Based on the final modified Rankin Scale (mRS) score, CK levels and MMT grade, 2 patients achieved complete remission, 1 patient showed partial remission, 3 patients exhibited no significant improvement and 4 patients experienced relapse during the disease process. Patients with complete remission achieved normalization of muscle strength and serum CK levels, along with antibody negativity, and were successfully weaned off medication. However, case 6 relapsed during gradual tapering of therapy after achieving normal muscle strength, normal serum CK levels, and antibody negativity, as the signal recognition particle (SRP) antibody reappeared strongly positive (+++) following almost 6 years of treatment. (Tables 4, 5, 6 and 7) Table 4Treatment of Patients with IMNMInitial therapyTime of steroid maintenance, monthsIVIGRTXOther immunotherapiesCase 1Methylprednisolone pulse therapy74 a2 g/kg, monthly, 17 times. 1 g/kg, once750 mg/m2, twiceHydroxychloroquine, azathioprine, methotrexate aCase 2Oral prednisolone, IVIG222 g/kg, monthly, 26 times. 1 g/kg, once750 mg/m2, once. 375 mg/m2, twiceMethotrexate, Mycophenolate mofetil a, tacrolimus, telitacicept, ofatumumabCase 3Methylprednisolone pulse therapy, IVIG, RTX26 a2 g/kg, monthly, 20 times. 1 g/kg, monthly, twice750 mg/m2, twiceMethotrexate aCase 4Methylprednisolone pulse therapy, IVIG, RTX34 a2 g/kg, monthly, 15 times750 mg/m2, three timesMethotrexate a, tacrolimus aCase 5Methylprednisolone pulse therapy, IVIG36 a2 g/kg, onceNoMethotrexate aCase 6Methylprednisolone pulse therapy, IVIG372 g/kg, monthly, twice750 mg/m2, four times. 375 mg/m2, six timesMethotrexate, mycophenolate mofetil aCase 7Oral prednisolone, methotrexate9 a2 g/kg, monthly, 6 timesNoMethotrexate aCase 8Oral prednisolone442 g/kg, monthly, 6 timesNoMethotrexateCase 9Methylprednisolone pulse therapy, IVIG602 g/kg, monthly, 8 timesNoMethotrexateCase 10Oral prednisolone71 aNoNoMethotrexatea: Maintaining till last visit. IVIG: intravenous immunoglobulin; RTX: rituximab Table 4Treatment of Patients with IMNMInitial therapyTime of steroid maintenance, monthsIVIGRTXOther immunotherapiesCase 1Methylprednisolone pulse therapy74 a2 g/kg, monthly, 17 times. 1 g/kg, once750 mg/m2, twiceHydroxychloroquine, azathioprine, methotrexate aCase 2Oral prednisolone, IVIG222 g/kg, monthly, 26 times. 1 g/kg, once750 mg/m2, once. 375 mg/m2, twiceMethotrexate, Mycophenolate mofetil a, tacrolimus, telitacicept, ofatumumabCase 3Methylprednisolone pulse therapy, IVIG, RTX26 a2 g/kg, monthly, 20 times. 1 g/kg, monthly, twice750 mg/m2, twiceMethotrexate aCase 4Methylprednisolone pulse therapy, IVIG, RTX34 a2 g/kg, monthly, 15 times750 mg/m2, three timesMethotrexate a, tacrolimus aCase 5Methylprednisolone pulse therapy, IVIG36 a2 g/kg, onceNoMethotrexate aCase 6Methylprednisolone pulse therapy, IVIG372 g/kg, monthly, twice750 mg/m2, four times. 375 mg/m2, six timesMethotrexate, mycophenolate mofetil aCase 7Oral prednisolone, methotrexate9 a2 g/kg, monthly, 6 timesNoMethotrexate aCase 8Oral prednisolone442 g/kg, monthly, 6 timesNoMethotrexateCase 9Methylprednisolone pulse therapy, IVIG602 g/kg, monthly, 8 timesNoMethotrexateCase 10Oral prednisolone71 aNoNoMethotrexatea: Maintaining till last visit. IVIG: intravenous immunoglobulin; RTX: rituximab Treatment of Patients with IMNM a: Maintaining till last visit. IVIG: intravenous immunoglobulin; RTX: rituximab Table 5Follow-up data of IMNM PatientsFollow-up time, monthsInitial MMT Grade*Best MMT GradeFinal MMT GradeInitial mRSBest mRSFinal mRSInitial CK (U/L)Highest CK (U/L)Last CK (U/L)Case 117 m4/35551113,52416,4851297Case 293 m4/455411327016,6742514Case 335 m5/455200580412,164589Case 435 m4/355411675710,4821778Case 541 m4/3554112080208094Case 6122 m4/35541128709495111Case 79 m4/35543311,83611,836668Case 896 m4/3554003136997458Case 982 m4/3555003207420174Case 1074 m4/35530047074916166* All are the key proximal muscle groups. The former is deltoid and the latter is quadriceps Table 5Follow-up data of IMNM PatientsFollow-up time, monthsInitial MMT Grade*Best MMT GradeFinal MMT GradeInitial mRSBest mRSFinal mRSInitial CK (U/L)Highest CK (U/L)Last CK (U/L)Case 117 m4/35551113,52416,4851297Case 293 m4/455411327016,6742514Case 335 m5/455200580412,164589Case 435 m4/355411675710,4821778Case 541 m4/3554112080208094Case 6122 m4/35541128709495111Case 79 m4/35543311,83611,836668Case 896 m4/3554003136997458Case 982 m4/3555003207420174Case 1074 m4/35530047074916166* All are the key proximal muscle groups. The former is deltoid and the latter is quadriceps Follow-up data of IMNM Patients * All are the key proximal muscle groups. The former is deltoid and the latter is quadriceps Table 6Treatment response of IMNM patientsTreatment responseTotal (n = 10)Complete remission, n(%)2(20%)Partial remission, n(%)1(10%)No significant improvement, n(%)3(30%)Relapse, n(%)4(40%) Table 6Treatment response of IMNM patientsTreatment responseTotal (n = 10)Complete remission, n(%)2(20%)Partial remission, n(%)1(10%)No significant improvement, n(%)3(30%)Relapse, n(%)4(40%) Treatment response of IMNM patients Table 7The outcome of patientsOutcomeTime to outcome#, monthsCase 1no significant remission86Case 2relapse42Case 3relapse11Case 4no significant remission27Case 5complete remission36Case 6relapse20Case 7no significant remission9Case 8relapse12Case 9complete remission82Case 10partial remission74# The time is calculated from initial treatment Table 7The outcome of patientsOutcomeTime to outcome#, monthsCase 1no significant remission86Case 2relapse42Case 3relapse11Case 4no significant remission27Case 5complete remission36Case 6relapse20Case 7no significant remission9Case 8relapse12Case 9complete remission82Case 10partial remission74# The time is calculated from initial treatment The outcome of patients # The time is calculated from initial treatment Discussion Apart from typical manifestations of IMNM, multiple atypical clinical phenotypes may occur during disease progression, such as asymptomatic hyper CK level, limb-girdle muscular dystrophy-like phenotype, facioscapulohumeral muscular dystrophy-like phenotype and distal myopathy phenotype [15]. In this study, all pediatric patients were hospitalized due to limb weakness, predominantly involving proximal limb muscles, with three patients exhibiting axial muscle weakness. Five patients had previously experienced other symptoms for at least one year before the onset of weakness, including elevated serum CK levels or rash like DM’s, which had not been recognized or appropriately addressed by their families. Therefore, rash and elevated serum CK levels may manifest early in pediatric IMNM; however, there is no statistical evidence supporting this observation currently, necessitating confirmation through large cohort studies. Based on this finding, in children with unexplained rash and elevated CK levels, even in the absence of muscle weakness, testing for myositis-specific antibodies should be considered to facilitate early diagnosis. Extra muscular manifestations of pediatric IMNM may include rash, heart failure, Raynaud’s phenomenon, interstitial lung disease, and malignancy. In our study, four patients exhibited periorbital rash, but none developed heart failure, Raynaud’s phenomenon, interstitial lung disease, or malignancy. Similarly, a previous single-center retrospective cohort study in China involving 55 pediatric IMNM patients found no cases with Raynaud’s phenomenon, interstitial lung disease, or malignancy [16]. Therefore, larger cohort studies are warranted to clarify the prevalence of extra muscular manifestations among Chinese pediatric patients with IMNM. Many studies have demonstrated that exposure to statin therapy is associated with adult IMNM patients who are positive for anti-HMGCR antibodies [17–19]. Statins are widely used to treat dyslipidemia and reduce the risk of cardiovascular diseases, but there is no research reporting the pediatric IMNM exposing to statins. In the study, none of these patients have been exposed to statins, which may be attributable to the fact that dyslipidemia and cardiovascular diseases predominantly occur in middle-aged people and elderly individuals. The degree of muscle fat infiltration and edema in IMNM is not synchronous. As the disease progresses, muscle edema gradually decreases, whereas fat infiltration remains stable or worsens. Previous literature lacks descriptions of MRI characteristics of the thigh muscles in pediatric IMNM. In patients with shorter disease duration, thigh muscle edema is the predominant lesion, while those with longer disease duration exhibit higher fat infiltration scores. Nevertheless, fat infiltration can occur during the early stages of the disease. In this study, fat infiltration primarily affected the gluteus maximus, followed by the adductor magnus, with the most severe fat infiltration observed in the gluteus maximus. The most frequently involved muscle for edema in the thigh was the adductor magnus, followed by the gluteus maximus. This distribution corresponds with the clinical presentation of IMNM, which typically manifests as proximal limb weakness. Although MRI constitutes just one element of the diagnostic criteria for antibody-negative IMNM, clinicians routinely perform muscle MRI during the diagnostic process, as the extent of muscle fat infiltration or edema identified by MRI may serve as a marker reflecting disease severity [20]. The diagnostic criteria for IMNM proposed at the 224th International Symposium are categorized into antibody-positive and antibody-negative criteria [4]. In the absence of specific autoantibodies, diagnosis requires integration of muscle pathology, electromyography, and muscle MRI findings. Due to the unique characteristics of pediatric patients, few underwent muscle biopsy, in contrast to adults. In this study, pathological results were available from only one pediatric case. Case 2 was initially suspected to have muscular dystrophy based on elevated CK levels and histopathological findings. However, the diagnosis of IMNM was confirmed after the development of muscle weakness and subsequent detection of muscle inflammation antibodies. This diagnostic challenge arises from overlapping histopathological features between IMNM and muscular dystrophy, leading to frequent misdiagnosis in the early stages. Previous cohort studies have also reported that pediatric IMNM can present with two types of muscle pathology: necrotizing myopathy and features mimicking muscular dystrophy, with the latter being more common [16]. Therefore, in patients presenting with elevated CK levels, testing for myositis-specific antibodies is essential for accurate diagnosis. The typical myopathological features of IMNM include myofiber necrosis and regeneration, with or without inflammatory cell infiltration, which constitutes one of the pathological diagnostic criteria [4]. However, these features are not specific to IMNM and can also be observed in other myopathies that involve myofiber necrosis. In addition to the evaluation of routine histological stains under light microscopy, immunohistochemical analysis is required for the diagnosis of antibody-negative IMNM. Currently, no consensus exists regarding the immunohistochemical characteristics of IMNM. A previous study evaluated the sensitivity and specificity of MHC-I and MHC-Ⅱ immunostaining in the diagnosis of IIMs. The findings indicated that upregulation of MHC-Ⅰ expression may represent a nonspecific and common secondary response to muscle injury, whereas MHC-Ⅱ expression in IIMs demonstrates high specificity with moderate sensitivity [21]. Increased MHC-Ⅰ expression in muscle fibers is frequently observed in patients positive for anti-HMGCR antibodies, supporting the immune-mediated pathogenesis of the disease, although it lacks specificity [22]. In contrast, MHC-Ⅱ expression is rarely detected in IMNM and may serve as one of the exclusions. Deposition of the complement MAC is also commonly observed in HMGCR patients, but it may also be present in those with DM and ASS [23]. Although muscle biopsy remains the gold standard for diagnosing IMNM, its pathological features lack specificity. In this study, only one patient had the muscle biopsy data because muscle biopsy is an invasive procedure, and the level of parental cooperation is often suboptimal. Consequently, antibody-negative patients are likely to be underrepresented in IMNM diagnoses. Therefore, a comprehensive diagnostic approach is necessary, incorporating clinical history, physical examination findings, serum CK levels, specific antibody testing, and muscle imaging findings. The lack of muscle pathology testing prevents the definitive diagnosis of seronegative patients; however, due to its invasiveness, confirming the diagnosis in seronegative pediatric patients remains a substantial challenge. Treatment of IMNM typically involves the administration of glucocorticoids, immunosuppressive agents, immunoglobulins, and biologic targeted therapies. According to the 2022 British Society for Rheumatology Guidelines for Juvenile IIM, high-dose glucocorticoids combined with methotrexate are recommended as first-line therapy for most pediatric patients. Mycophenolate mofetil has demonstrated efficacy in improving both cutaneous and muscular manifestations, whereas IVIG, RTX, and cyclophosphamide are primarily reserved for severe or refractory IIM cases [24]. In this study, all pediatric patients received either intravenous or oral glucocorticoids as initial treatment. Oral glucocorticoid therapy plays a significant role in maintenance treatment, but its detailed maintenance duration remains unclear. In Takayuki Kishi and his team members’ study, the median time to final corticosteroid discontinuation was 51 months, 82 months for complete clinical response and 92 months for remission among JDM patients [25]. Despite the use of minimal glucocorticoid doses during follow-up therapy, adverse effects associated with long-term use cannot be overlooked, including osteopenia, obesity, delay in statural growth, delayed puberty, cataracts, hypertension, infections (due to immunosuppressive effects) and digestive and metabolic disorders [26]. For children in the growth and developmental period, these adverse effects are particularly pronounced, with growth retardation being the most severe [27]. Many parents expressed concern regarding the potential adverse effects of long-term glucocorticoid use on growth and development. But those safety and adverse event data were not systematically captured in this retrospective study and any benefit-risk assessment is limited. Therefore, prospective studies are urgently needed to establish the minimal effective duration of glucocorticoid therapy in pediatric IMNM, aiming to balance efficacy with the minimization of long-term adverse effects on growth and development. IVIG and biologics have been widely applied in refractory IMNM patients and some studies consider that IVIG may prove to be a valuable addition to early and aggressive induction regimens in patients with anti-HMGCR IMNM [4, 28]. Determining criteria for escalation and de-escalation of therapy remains challenging. Suh and Amato emphasized that IVIG monotherapy can be highly effective in the treatment of anti-HMGCR IMNM, and that a short course (3–5 days) of intravenous methylprednisolone may be considered at disease onset in patients with severe weakness [18]. Furthermore, the 224th ENMC International Workshop recommended that IVIG and RTX may be initiated concurrently, with subsequent re-dosing or transition to maintenance therapy, guided by muscle strength and CK levels, while continuing concomitant treatments [4]. In this study, two children achieved complete remission and ultimately discontinued medication. For patient 8, CK levels normalized, and prednisolone dosage reduction commenced three months later, with gradual addition of methotrexate. Eight months later, she stopped use prednisolone due to medication shortage, resulting in worsening limb strength and disease relapse. However, after reusing the therapy of prednisolone and methotrexate, combined with IVIG for seven months, prednisolone tapering began when CK levels were normal and antibodies became negative. Whereas, another patient began gradual prednisolone reduction one month after CK normalization and did not experience relapse. Compared with these two treatment courses, the latter patient had received methylprednisolone pulse therapy and IVIG at the early stage of disease onset. A review supports early and aggressive immunotherapy to minimize irreversible muscle damage and fatty replacement, though these interventions are often not completely effective [29]. One patient in this study received biologic targeted therapy with telitacicept and ofatumumab during the disease course. Telitacicept is primarily approved for the treatment of systemic lupus erythematosus (SLE), myasthenia gravis (MG), rheumatoid arthritis (RA), and many kinds of kidney disease. Its efficacy and safety in autoimmune disorders having been well demonstrated in clinical practice [30]. Ofatumumab is a B-cell-targeted therapy and mostly used for multiple sclerosis (MS) [31]. However, neither of these agents has been previously reported for the treatment of idiopathic myositis. In this study, due to suboptimal clinical response, this patient was subsequently transitioned to IVIG therapy. Sequential immunosuppressive therapy in this cohort consisted of low-dose glucocorticoids combined with an immunosuppressant. Nevertheless, due to the limited sample size, no definitive conclusions can be drawn regarding the optimal combination regimen. Conclusion This study retrospectively analyzed the clinical features, therapeutic approaches, and outcomes of antibody-positive pediatric IMNM patients based on clinical presentations, laboratory findings, imaging studies, and muscle histopathology. However, it was a single-center, retrospective case series with a limited sample size and did not include an analysis of prognostic factors. Future research should prioritize multicenter, prospective, large-scale cohort studies to further delineate the clinical characteristics and prognostic determinants of pediatric IMNM, thereby supporting the development of evidence-based prognostic evaluation tools and individualized therapeutic strategies. Limitation Firstly, as a single-center retrospective study, the number of patients was limited (n = 10), which reduces the statistical power and increases susceptibility to random bias. Additionally, patients with negative antibodies were excluded from this study, primarily due to challenges in performing muscle biopsy in pediatric patients with antibody-negative idiopathic inflammatory myopathies (IIMs), which significantly contributes to spectrum bias and compromises external validity. Furthermore, the absence of standardized pediatric myositis outcome measures (MMT-8, CMAS, IMACS core set) represents a limitation of this retrospective study. Future prospective investigations should incorporate these validated tools to enable more precise functional assessment and cross-trial comparisons. Moreover, the safety data and adverse event profiles could not be collected due to the absence of relevant information, but such data will be included in future studies. Finally, as a retrospective study, it is inherently difficult to establish definitive causal relationships between exposures and outcomes, fully control for unmeasured confounding variables, and avoid selection bias. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1